

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Boill Healthcare Holdings Limited**

### **保集健康控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 01246)**

## **PROFIT WARNING**

This announcement is made by Boill Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the Board’s preliminary assessment of the unaudited consolidated management account of the Group for the year ended 31 March 2019 (the “**Period**”), the Group is expected to record a consolidated net loss of approximately HK\$220 million for the Period, as compared with the consolidated net loss of approximately HK\$195 million for the year ended 31 March 2018. Such expected substantial consolidated net loss for the Period was mainly due to the following:

- (i) The revenue of sales of properties has declined by approximately 30% for the Period as compared with the corresponding year ended 31 March 2018 resulting from the weakened demand of our potential home buying customers due to deterioration of their overall financial condition brought by the uncertain global macro-economic environment;
- (ii) The revenue of the foundation piling business has dropped more than 60% for the Period as compared with the corresponding year ended 31 March 2018 resulting from the discounts offered for tendered projects involving intense market competition with other subcontractors. However, the other costs (including depreciation and salaries) have not dropped in proportion with the decreased revenue;

- (iii) The construction of the project in Shanghai has not yet been completed and no revenue has been recognised while the cost incurred for daily operation was not less than HK\$14 million for the Period (2018: approximately HK\$5 million);
- (iv) Loss on fair value of approximately HK\$27 million on investment properties under construction were derived for the Period (2018: gain on fair value of approximately HK\$17 million); and
- (v) No significant gains on disposal of equity investment were derived for the Period (2018: approximately HK\$58 million).

The Company is still in the process of finalising the annual results of the Group for the Period. The information contained in this announcement is only based on preliminary assessment made by the Board with reference to the unaudited consolidated management accounts of the Group for the Period, which are subject to adjustments and final review by the Company and its auditor.

The Shareholders and potential investors are advised to read carefully the annual results announcement of the Group for the Period for further details, which is expected to be published on 28 June 2019.

**The Shareholders and potential investors are advised to exercise caution when dealing securities of the Company.**

By order of the Board  
**Boill Healthcare Holdings Limited**  
**Dai Dong Xing**  
*Executive Director and Chairman*

Hong Kong, 14 June 2019

*As at the date of this announcement, the Company has (i) two executive Directors, namely Mr. Dai Dong Xing and Mr. Zhang Sheng Hai; (ii) one non-executive Director, namely Mr. Chui Kwong Kau; and (iii) three independent non-executive Directors, namely Mr. Chan Chi Keung Billy, Mr. Xu Liang Wei and Mr. Wang Zhe.*